ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 1920 • 2019 ACR/ARP Annual Meeting

    School Nurse Education for Juvenile Idiopathic Arthritis

    W. Blaine Lapin1, Carleigh Kutac 2, Danielle Guttman-Lapin 3, Amanda Brown 2, Eyal Muscal 2 and Filiz Seeborg 2, 1Baylor College of Medicine, Connecticut Children's Medical Center, Houston, TX, 2Baylor College of Medicine, Houston, TX, 3Aldine Independent School District, Houston, TX

    Background/Purpose: There is a paucity of literature on the challenges children with JIA face at school. Despite treatment advances, children with JIA often rate their…
  • Abstract Number: 2714 • 2019 ACR/ARP Annual Meeting

    Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry

    Melissa Mannion1, Fenglong Xie 2 and Timothy Beukelman 3, 1University of Alabama at Birmingham, Alabama, 2University of Alabama at Birmingham, Birmingham, 3University of Alabama Birmingham, Birmingham, AL

    Background/Purpose: Inactive disease is the stated goal of treatment in juvenile idiopathic arthritis (JIA) and is typically measured by a composite score that combines several…
  • Abstract Number: 781 • 2019 ACR/ARP Annual Meeting

    Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?

    Charlene Foley1, Achilleas Floudas 2, Sharon Ansboro 2, Mary Canavan 2, Monika Biniecka 2, Emma Jane MacDermott 3, Ronan Mullan 4, Gerry Wilson 5, Ursula Fearon 6 and Orla Killeen 7, 1Great Ormond Street Hospital, London, Ireland, 2TBSI, Dublin, Ireland, 3OLCHC, Dublin, Ireland, 4Tallaght Hospital, Dublin, Ireland, 5UCD, Dublin, Ireland, 6TBSI, Dublin, 7National Centre for Paediatric Rheumatology (NCPR), Our Lady’s Children’s Hospital Crumlin (OLCHC), Dublin, Ireland

    Background/Purpose: Down syndrome associated Arthritis (DA) is 20 times more common than JIA. It is an erosive, polyarticular RF negative arthritis with predominance in the…
  • Abstract Number: 1921 • 2019 ACR/ARP Annual Meeting

    Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

    Gaëlle Chédeville1, Michelle Batthish 2, Roberta Berard 3, Roxana Bolaria 4, Alessandra Bruns 5, David Cabral 6, Ciaran Duffy 7, Kerstin Gerhold 8, Tommy Gerschman 6, Jean-Philippe Proulx-Gauthier 9, Alan Rosenberg 10, Dax Rumsey 11, Heinrike Schmeling 12, Natalie Shiff 13, Gordon Soon 14, Lori Tucker 15 and Jaime Guzman 6, 1The Montreal Children's Hospital, McGill University, Montreal, Canada, 2McMaster University, Hamilton, Canada, 3Children's Hospital, London Health Sciences Centre, London, Canada, 4University of British Columbia, Victoria, BC, Canada, 5Université de Sherbrooke, Sherbrooke, QC, Canada, 6University of British Columbia, Vancouver, BC, Canada, 7University of Ottawa, Ottawa, ON, Canada, 8University of Manitoba, Winnipeg, MB, Canada, 9Université Laval, Québec, QC, Canada, 10University of Saskatchewan, Saskatoon, SK, Canada, 11University of Alberta, Edmonton, AB, Canada, 12Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 13University of Florida, Gainesville, FL, 14University of Toronto, Toronto, ON, Canada, 15British Columbia Children’s Hospital, Vancouver, Canada

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and many medications are available to control the disease. While physician-reported adverse…
  • Abstract Number: 2715 • 2019 ACR/ARP Annual Meeting

    Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset

    Ruth Costello1, Janet McDonagh 2, Will Dixon 1, Kimme Hyrich 2 and Jenny Humphreys 1, 1Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, 2Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom / NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common childhood onset inflammatory arthritis.  The last estimates of incidence of this disease in the United Kingdom…
  • Abstract Number: 782 • 2019 ACR/ARP Annual Meeting

    Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion

    Erdal Sag1, Selcan Demir 2, Morten A. Nielsen 3, Malene Hvid 4, Egemen Turhan 5, Yelda Bilginer 2, Seza Ozen 6 and Bent Deleuran 7, 1Hacettepe University, Ankara, Turkey, 2Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey, 3Department of Biomedicine, Aarhus University, Aarhus, Denmark, 4Department of Biomedicine; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, 5Department of Orthopedics and Traumatology, Hacettepe University, Ankara, Turkey, 6Hacettepe University Hospital, Ankara, Turkey, 7Department of Biomedicine; Department of Rheumatology, Aarhus University, Aarhus, Denmark

    Background/Purpose: Activated T cells are involved in the pathogenesis of the synovitis in oligoarticular Juvenile Idiopathic Arthritis (o-JIA). T cell activation is counter-balanced via co-inhibitory…
  • Abstract Number: 1923 • 2019 ACR/ARP Annual Meeting

    Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials

    Hermine Brunner1, Chen Chen 1, Alberto Martini 2, Graciela Espada 2, Rik Joos 2, Jonathan Akikusa 2, Jeffrey Chaitow 2, Maria Luz Gámir Gámir 2, Yukiko Kimura 3, Christoph Rietschel 2, Daniel Siri 2, Elzbieta Smolewska 2, Heinrike Schmeling 1, Diane Brown 1, Fabrizio De Benedetti 4, Daniel J. Lovell 5, Bin Huang 1 and Nicolino Ruperto 2, 1Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 3Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, 4Bambino Gesù Children’s Hospital, Rome, Italy, 5Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati

    Background/Purpose: Tocilizumab (TCZ) was approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) based on the results of…
  • Abstract Number: 2716 • 2019 ACR/ARP Annual Meeting

    Long Term Outcomes of Childhood Onset Rheumatoid Arthritis

    Rebecca Overbury1, Aimee Hersh 2, CJ Inman 2, Sara Stern 2, Karen James 2 and John Bohnsack 3, 1Assisstant Professor, University of Utah, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3University of Utah School of Medicine, Salt Lake City, UT

    Background/Purpose: Childhood onset rheumatoid arthritis (CORA) describes patients with juvenile idiopathic arthritis (JIA) who are rheumatoid factor (RF) or anti-cyclic citrullinated antibody (ACPA) positive. Phenotypically,…
  • Abstract Number: 785 • 2019 ACR/ARP Annual Meeting

    Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience

    Muhammad Shipa1, Anastasia-vasiliki Madenidou 2, vera Choida 1, Anna Radziszewska 3, corinne fisher 4, coziana ciurtin 1, maria Leandro 1 and Debajit Sen 1, 1Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, London, United Kingdom, 2Centre for Adolescent Rheumatology, University College London London, UK, LOndon, 3University College London, London, United Kingdom, 4Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, lonodn, United Kingdom

    Background/Purpose: Biologics have transformed the treatment of Juvenile idiopathic arthritis (JIA) and escalation toTumour Necrosis Factor - α inhibitors (TNFi) after failure of methotrexate (MTX)…
  • Abstract Number: 1925 • 2019 ACR/ARP Annual Meeting

    Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis

    Francesca Ridella 1, Giedre Januskeviciute 2, Chiara Trincianti 3, Evert Hendrik Pieter Van Dijkhuizen 4, Gabriella Giancane 5, Serena Pastore 6, Kirsten Minden 7, Maria Ekelund 8, Patrizia Barone 9, Matilda Laday 10, Nicolino Ruperto 11, Angelo Ravelli 12 and Alessandro Consolaro13, 1Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genova, Italy, 2Klaipeda Children's Hospital, Klaipeda, Lithuania, Klaipeda, Lithuania, 3Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genoa, Italy, 4Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, 5Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, Italy, 6Institute for Maternal and Child Health IRCCS "Burlo Garofolo," Trieste, Italy, Trieste, Italy, 7German Rheumatism Research Centre Berlin, and Charité University Medicine, Department of Rheumatology and Clinical Immunology, Berlin, Germany, Berlin, Germany, 8Ryhov County Hospital, Futurum - the Academy for health and care, Jonkoping, Sweden, Jonkoping, Sweden, 9Department of Pediatrics, University of Catania, Catania, Italy, Catania, Italy, 10Spitalul Clinic Județean De Urgenta, Tîrgu-Mures, Romania, Tîrgu-Mures, Romania, 11Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 12IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 13Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy

    Background/Purpose: The assessment of disease activity plays a pivotal role in the management of children with juvenile idiopathic arthritis (JIA). Most recent recommendations require that…
  • Abstract Number: 2718 • 2019 ACR/ARP Annual Meeting

    A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis

    Kiana Taba1 and Elizabeth Ortiz 2, 1University of Southern California, LAGUNA HILLS, CA, 2LAC+USC/Keck Medicine of USC, Los Angeles

    Background/Purpose: The use of biologic DMARDs (bDMARDs) has vastly changed the treatment of autoimmune arthritis, both Rheumatoid Arthritis (RA) and polyarticular and oligoarticular Juvenile Idiopathic…
  • Abstract Number: 2703 • 2019 ACR/ARP Annual Meeting

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices

    Sarah Ringold 1, George Tomlinson 2, Pamela Weiss 3, Laura Schanberg 4, Mary Ellen Riordan 5, Anne Dennos 6, Vincent Del Gaizo 7, Katherine Murphy 8, Brian Feldman 9 and Yukiko Kimura10, 1Seattle Children's, Seattle, 2University of Toronto, Toronto, ON, Canada, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4Duke University Medical Center, Durham, NC, 5Joseph M Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, NJ, 6Duke Clinical Research Institute, Durham, NC, 7Childhood Arthritis & Rheumatology Research Alliance, Whitehouse Station, NJ, 8Louisiana Office of Public Health, New Orleans, LA, 9University of Toronto & The Hospital for Sick Children, Toronto, ON, Canada, 10Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH

    Background/Purpose: There continues to be uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance…
  • Abstract Number: 786 • 2019 ACR/ARP Annual Meeting

    Distinguishing S100 Proteins and Cytokine Levels Between Active and Inactive Uveitis in Children with Juvenile Idiopathic Arthritis

    Jackeline Rodriguez-Smith1, Virginia Utz 2, Sherry Thornton 1, Grant Schulert 1, Adam Kauffman 3, Alyssa Sproles 1, Najima Mwase 1, Theresa Hennard 4, Alexei A. Grom 1, Mekibib Altaye 5, Gary Holland 6 and Sheila Angeles-Han 7, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Ophthalmology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Cincinnati Eye Institute and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 5Divison of Biostatistics and Epidemiology and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, 6UCLA Stein Eye Institute and David Geffen School of Medicine at University of California, Los Angeles, Ca, Los Angeles, CA, 7Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati

    Background/Purpose: Uveitis occurs in 10-20% of children with Juvenile Idiopathic Arthritis (JIA) and is typically asymptomatic. Ocular complications occur in 50% of children, (i.e. cataracts,…
  • Abstract Number: 2096 • 2019 ACR/ARP Annual Meeting

    An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients

    Valeria Valerio1, Maria Bazan 1, Mianbo Wang 2, Bruce Mazer 1, Elizabeth M. Hazel 3, Christian Pineau 4, Sasha Bernatsky 5, Brian Ward 6 and Ines Colmegna 6, 1The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, 3McGill University Health Centre, Montreal, Canada, 4McGill University Health Centre, Montreal, QC, Canada, 5McGill University Health Center, Montreal, Canada, 6McGill University Health Center, Montreal, QC, Canada

    Background/Purpose: Annual vaccination with inactivated influenza vaccine is recommended for adults with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Despite this, influenza immunization coverage…
  • Abstract Number: 2724 • 2019 ACR/ARP Annual Meeting

    Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA

    Alexander Solyom1, Erik Sundberg 2, John Mitchell 3, Christina Grant 4, Carlos Ferreira 5, Paul Harmatz 6, Neslihan Mungan 7, Fatma Bulut 7, Christina Lampe 8, Andreas Hahn 8, Norberto Guelbert 9, Nur Arslan 10, Balahan Makay 10, Ratna Puri 11, Sunita Bijarnia-Mahay 11, Laila Selim 12, Iman Gamal el Din 12, Seema Kapoor 13, Maja DiRocco 14, Seza Ozen 15, Ezgi Batu 15, Gulden Gokcay 16, Marta Torcoletti 17, Alan Kimura 18 and Bo Magnusson 2, 1Enzyvant, Basel, Switzerland, 2Karolinska University Hospital, Stockholm, Sweden, 3Montreal Children's Hospital, Montreal, Canada, 4Children's National Medical Center, Washingotn, DC, 5Children's National Medical Center, Washington, DC, 6UCSF Benioff Children's Hospital Oakland, Oakland, CA, 7Cukurova University Hospital, Adana, Turkey, 8University Hospital Giessen, Giessen, Germany, 9Children's Hospital of Cordoba, Cordoba, Argentina, 10Dokuz Eylul University Hospital, Izmir, Turkey, 11Sir Ganga Ram Hospital, Delhi, India, 12Cairo University Children's Hospital, Cairo, Egypt, 1313Lok Nayak Hospital and Maulana Azad Medical College, Delhi, India, 14Istituto Giannina Gaslini, Genoa, Italy, 15Hacettepe University Hospital, Ankara, Turkey, 16Istanbul University, Istanbul, Turkey, 17University of Milan, Milan, Italy, 18Enzyvant, Cambridge, MA

    Background/Purpose: The cardinal clinical symptoms of Farber disease (arthritis/contractures, subcutaneous granulomatous nodules, dysphonia) may be misdiagnosed as JIA. Mutations in the ASAH1 gene and the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology